Metastatic castrate-resistant prostate cancer: New landscape, new challenges

British Journal of Medical and Surgical Urology

Volumn 4, Issue SUPPL. 1, 2011, Pages

  Bahl, Amit ^a   Persad, Raj ^b  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Chemotherapy; CRPC; Metastatic prostate cancer; Prostate cancer

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; ALPHARADIN; CABAZITAXEL; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MITOXANTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; RADIOPHARMACEUTICAL AGENT; TESTOSTERONE; UNCLASSIFIED DRUG;

ANDROGEN SYNTHESIS; ANTIGEN PRESENTING CELL; ARTICLE; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; DISEASE COURSE; DRUG EFFICACY; FEBRILE NEUTROPENIA; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LEUKAPHERESIS; METASTASIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TESTOSTERONE BLOOD LEVEL;

EID: 80051691317     PISSN: 18759742     EISSN: 18759750     Source Type: Journal    
DOI: 10.1016/j.bjmsu.2011.05.003     Document Type: Article

References (26)

1. Heidenreich A, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, et al. Guidelines on prostate cancer. EAU, [accessed April 2011]. http://www.uroweb.org/gls/pdf/Prostate%2520Cancer%25202010%2520June%252017th.pdf;%202010.
2. Anderson J. The need for improved therapeutic strategies for patients with metastatic hormone-refractory prostate cancer. Eur Urol Suppl 2006, 5:811-816.
3. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
4. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26:242-245.
5. National Institute for Health and Clinical Excellence. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer. (Technology Appraisal 101). NICE, ; 2006 [accessed April 2011]. http://www.nice.org.uk/nicemedia/live/11578/33348/33348.pdf.
6. Mathew P., Dipaola R. Taxane refractory prostate cancer. J Urol 2007, 178:S36-S41.
7. Bissery M.C. Preclinical evaluation of new taxanes. Curr Pharm Des 2001, 7:1251-1257.
8. Pivot X., Koralewski P., Hidalgo J.L., Chan A., Gonçxalves A., Schwartsmann G., et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008, 19:1547-1552.
9. Mita A.C., Denis L.J., Rowinsky E.K., de Bono J.S., Goetz A.D., Ochoa L., et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009, 15:723-730.
10. de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.-P., Kocak I., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
11. Dorff T.B., Quinn D.I. Cabazitaxel in prostate cancer: stretching a string. Lancet 2010, 376:1119-1120.
12. Danila D.C., Morris M.J., de Bono J.S., Ryan C.J., Denmeade S.R., Smith M.R., et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010, 20:1496-1501.
13. Ryan C.J., Smith M.R., Fong L., Rosenberg J.E., Kantoff P., Raynaud F., et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010, 28:1481-1488.
14. Reid A.H., Attard G., Danila D.C., Oommen N.B., Olmos D., Fong P.C., et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010, 28:1489-1495.
15. de Bono JS, Logothetis CJ, Fizazi K, North S, Chu L, Chi KN, et al. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. Presented at ESMO, Milan, October 2010; Abstract LBA5.
16. Kantoff P.W., Higano C.S., Shore N.D., Berger R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
17. Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
18. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
19. ClinicalTrials.gov. Safety and efficacy study of MDV3100 in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy (AFFIRM), [accessed April 2011]. http://clinicaltrials.gov/ct2/show/NCT00974311.
20. ClinicalTrials.gov. A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL), [accessed April 2011]. http://clinicaltrials.gov/ct2/show/NCT01212991.
21. Sonpavde G., Periman P.O., Bernold D., Weckstein D., Fleming M.T., Galsky M.D., et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010, 21:319-324.
22. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
23. Kantoff P.W., Schuetz T.J., Blumenstein B.A., Glode L.M., Bilhartz D.L., Wyand M., et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28:1099-1105.
24. Nilsson S., Franzén L., Tyrrell C., Blom R., Tennvall J., Lennernäs B., et al. Radium-223 in the treatment of metastatic hormone refractory prostate cancer (HRPC): results from a randomized, placebo controlled, phase II study. J Clin Oncol 2007, 25. Abstract 5071.
25. ClinicalTrials.gov. A phase III study of alpharadin (radium-223) in patients with symptomatic hormone refractory prostate cancer with skeletal metastases (ALSYMPCA), [accessed April 2011]. http://clinicaltrials.gov/ct2/show/NCT00699751.
26. ClinicalTrials.gov. Androgen suppression alone or combined with zoledronate, docetaxel, prednisolone, and/or celecoxib in treating patients with locally advanced or metastatic prostate cancer, [accessed April 2011]. http://clinicaltrials.gov/ct2/show/NCT00268476.